Name /Anbogen Therapeutics - NHRI
Address /No. 27, Alley 2, Lane 250, Section 5, Nanjing East Road, Songshan District, Taipei 105, Taiwan
Expecting startup year /
No. of team members /
Name /Dr. Tsu-An Hsu
Telephone /(Work) 886-2-2742-1839
Anbogen Therapeutics is a clinical stage biopharmaceutical company founded in 2019, based in Taipei, Taiwan and focused on developing best-to-patient precision medicine in oncology. Founders and the executive team deeply rooted in science and with extensive experience in medicinal chemistry, drug discovery/development, company operation and IPO success. Currently, the lead pipeline drug, ABT-101, is the small molecule drug targeting NSCLC patients carrying exon 20 insertions in HER2 will enter PhI/II escalation study in Q4 of 2021. ABT-201, is a KRAS inhibitor under hit-to-lead development. Anbogen Therapeutics is raising 10 mm USD for its series A financing.
Anbogen Therapeutic’s lead pipeline drug, ABT-101, is an oral tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients harboring exon 20 insertions (e20i) in HER2. Currently, chemotherapy remains the main therapy for this type of patient population. Anbogen’s series of head-to-head comparison studies demonstrate ABT-101 is less toxic and more effective than other competitors’ pipeline drugs. That constitutes ABT-101 has a broader therapeutic window and holds the best-in-class drug potential toward e20i in HER2. The pharmacokinetics and toxicology profiles of ABT-101 have been evaluated in various animal models and six cancer patients. In addition to ABT-101, ABT-201, is a KRAS inhibitor under hit-to-lead development. ABT-301, another precision oncology medicine, is under in-licensing process. Anbogen Therapeutics aims to develop best-to-patient and paradigm-shifting precision oncology medicines.
Name /Ms. IChu-Tsai
Phone /886- 037-206-166 ext. 33226